Comparison

Sitagliptin (phosphate monohydrate) European Partner

Item no. HY-13749B-10mM
Manufacturer MedChem Express
CASRN 654671-77-9
Amount 10 mM/1 mL
Quantity options 100 mg 10 mM/1 mL 1 g 200 mg 500 mg
Category
Type Inhibitors
Specific against other
Purity 99.83
Citations [1]Thomas, L., et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of acti|[2]Kim, S.J., et al., Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes, 2009. 58(3): p. 641-51.|[3]Sangle, G.V., et al., Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a GLP-1 secretagogue. Endocrinology, 2012. 153(2): p. 564-73.|[4]Kim, S.J., et al., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes, 2008. 57(5): p. 1331-9.|[5]Beconi, M.G., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, 2007. 35(4): p. 525-32.
Biomed Pharmacother. 2023 Mar 24;162:114555.|bioRxiv. 2023 Nov 4.|Biochem Pharmacol. 2023 Oct 5:115846.|Biochim Biophys Acta Mol Basis Dis. 2024 Jul 25:167433.|Cell Death Dis. 2021 Oct 11;12(10):928.|Exp Cell Res. 2024 Sep 12;442(2):114254.|Front Oncol. 24 September 2021.|iScience. 2023 Feb.|J Adv Res. 2024 Oct 5:S2090-1232(24)00433-8.|J Biol Chem. 2018 Dec 7;293(49):18864-18878. |J Nanobiotechnology. 2024 Oct 16;22(1):631.|J Sep Sci. 2021 Oct 28.|Korean J Physiol Pharmacol. 2021 Sep 1;25(5):425-437.|Life Metab. 2025 Feb 08.|Neurol Res. 2018 Sep;40(9):736-743.|Nutr Neurosci. 2018 Apr 26:1-17.|Nutrition. 2024 Aug 29.|Orebro University. 2024.|Oxid Med Cell Longev. 2019 Nov 15;2019:6181754.|Oxid Med Cell Longev. 2022 May 17;2022:2586305.|Research Square Preprint. 2024 Apr 25.|Sci Rep. 2019 Mar 11;9(1):4074.
Smiles [H]O[H].O=C(N1CC2=NN=C(C(F)(F)F)N2CC1)C[C@H](N)CC3=CC(F)=C(F)C=C3F.O=P(O)(O)O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias MK-0431 (phosphate monohydrate)
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Metabolism-protein/nucleotide metabolism
Manufacturer - Targets
Autophagy; Dipeptidyl Peptidase
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
523.32
Product Description
Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts[1].
Manufacturer - Research Area
Metabolic Disease; Cancer
Solubility
H2O : ≥ 33 mg/mL
Manufacturer - Pathway
Autophagy; Metabolic Enzyme/Protease
Clinical information
Launched
Isoform
DPP-4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mM/1 mL
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?